Published On: Wed, Sep 14th, 2016

Analysts’ Weekly Ratings Changes for Johnson & Johnson (JNJ)

A number of firms have modified their ratings and price targets on shares of Johnson & Johnson (NYSE: JNJ) recently:

9/13/2016 – Johnson & Johnson had its price target lowered by analysts at Jefferies Group from $119.00 to $115.00. They now have a “hold” rating on the stock.
9/13/2016 – Johnson & Johnson was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $133.00 price target on the stock. According to Zacks, “J&J’s Pharma segment is performing well despite challenges like generic competition for a few products, currency impact and lower HCV revenues. Contribution from new as well as core products, share buybacks and the restructuring initiative should help drive results. Although headwinds like negative currency movement, generics, pricing pressure, and soft global market conditions remain, we believe J&J’s diversified business model, deep pipeline, lack of cyclicality and strong financial position will continue helping the company pave its way through tough situations. We expect the company to continue pursuing bolt-on acquisitions and deals to boost its portfolio. J&J has a deep and promising pipeline with a good new product launch record. “
9/11/2016 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at Leerink Swann.
9/7/2016 – Johnson & Johnson had its “neutral” rating reaffirmed by analysts at BTIG Research.
8/25/2016 – Johnson & Johnson had its “neutral” rating reaffirmed by analysts at BTIG Research.
8/22/2016 – Johnson & Johnson was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $124.21 price target on the stock.
8/19/2016 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $142.00 price target on the stock.
8/8/2016 – Johnson & Johnson was upgraded by analysts at Vetr from a “sell” rating to a “hold” rating. They now have a $124.21 price target on the stock.
8/5/2016 – Johnson & Johnson was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $139.00 price target on the stock. According to Zacks, “J&J delivered another strong quarter with both earnings and revenues beating estimates. The Pharma segment continues to perform well despite challenges like generic competition for a few products, currency impact and lower HCV revenues. J&J also raised its outlook for 2016. Contribution from new as well as core products, share buybacks and the restructuring initiative should help drive results. Estimates are on the rise following second quarter results. Although headwinds like negative currency movement, generics, pricing pressure, and soft global market conditions remain, we believe J&J's diversified business model, deep pipeline, lack of cyclicality and strong financial position will continue helping the company pave its way through tough situations. We expect the company to continue pursuing bolt-on acquisitions and deals to boost its portfolio. J&J has a deep and promising pipeline with a good new product launch record”
8/4/2016 – Johnson & Johnson was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “J&J’s second quarter results were strong with the company beating on all fronts and raising its outlook for the year. The Pharma segment continues to perform well despite challenges like generic competition for a few products, currency impact and lower HCV revenues. Contribution from new as well as core products, share buybacks and the restructuring initiative should help drive results. Although headwinds like negative currency movement, generics, pricing pressure, and soft global market conditions remain, we believe J&J's diversified business model, deep pipeline, lack of cyclicality and strong financial position will continue helping the company pave its way through tough situations. We expect the company to continue pursuing bolt-on acquisitions and deals to boost its portfolio. J&J has a deep and promising pipeline with a good new product launch record.”
8/4/2016 – Johnson & Johnson had its price target raised by analysts at Jefferies Group from $113.00 to $119.00. They now have a “hold” rating on the stock.
7/21/2016 – Johnson & Johnson had its “hold” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $142.00 price target on the stock, up previously from $125.00.
7/20/2016 – Johnson & Johnson had its price target raised by analysts at Royal Bank Of Canada from $125.00 to $133.00. They now have an “outperform” rating on the stock.
7/20/2016 – Johnson & Johnson had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $132.00 price target on the stock.
7/20/2016 – Johnson & Johnson had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $140.00 price target on the stock, up previously from $125.00.
7/20/2016 – Johnson & Johnson had its “outperform” rating reaffirmed by analysts at RBC Capital Markets. They now have a $133.00 price target on the stock, up previously from $125.00.

Johnson & Johnson (NYSE:JNJ) opened at 117.61 on Wednesday. The firm’s 50-day moving average price is $121.42 and its 200-day moving average price is $115.71. Johnson & Johnson has a 12-month low of $89.90 and a 12-month high of $126.07. The stock has a market cap of $321.77 billion, a price-to-earnings ratio of 21.92 and a beta of 0.61.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 19th. The company reported $1.74 EPS for the quarter, topping analysts’ consensus estimates of $1.68 by $0.06. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. The firm had revenue of $18.50 billion for the quarter, compared to analysts’ expectations of $17.98 billion. On average, equities analysts predict that Johnson & Johnson will post $6.69 EPS for the current fiscal year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/14/analysts-weekly-ratings-changes-for-johnson-johnson-jnj.html

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 19th. Investors of record on Friday, August 5th were given a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a dividend yield of 0.99%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 60.15%.
In related news, VP Dominic J. Caruso sold 41,146 shares of the stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the sale, the vice president now directly owns 157,819 shares of the company’s stock, valued at $19,728,953.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Ronald A. Kapusta sold 2,935 shares of the stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $125.01, for a total value of $366,904.35. Following the sale, the chief accounting officer now directly owns 28,660 shares in the company, valued at $3,582,786.60. The disclosure for this sale can be found here. Corporate insiders own 0.11% of the company’s stock.
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>